Taranabant

Taranabant
Skeletal formula of taranabant
Space-filling model of the taranabant molecule
Clinical data
Routes of
administration		 Oral
ATC code
Legal status
Legal status
  • Investigational (failed)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard 100.207.983 Edit this at Wikidata
Chemical and physical data
Formula C27H25ClF3N3O2
Molar mass 515.95 g/mol
3D model (JSmol)
  (verify)

Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects.[1][2] It was discovered by Merck & Co.

In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central side effects, mainly depression and anxiety.[3][4][5][6]

See also

References

  1. ↑ Armstrong HE, Galka A, Lin LS, Lanza TJ Jr, Jewell JP, Shah SK, et al. "Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists." Bioorganic & Medicinal Chemistry Letters. 2007 Apr 15;17(8):2184-7. PMID 17293109. doi:10.1016/j.bmcl.2007.01.087
  2. ↑ Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, et al. "Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents." Journal of Pharmacology and Experimental Therapeutics. 2007 Jun;321(3):1013-22. PMID 17327489. doi:10.1124/jpet.106.118737
  3. ↑ "Press release by Merck". Retrieved October 2008. Check date values in: |accessdate= (help)
  4. ↑ Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM (May 2010). "A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study". International Journal of Obesity (2005). 34 (5): 919–35. doi:10.1038/ijo.2010.21. PMID 20157323.
  5. ↑ Kipnes MS, Hollander P, Fujioka K, Gantz I, Seck T, Erondu N, Shentu Y, Lu K, Suryawanshi S, Chou M, Johnson-Levonas AO, Heymsfield SB, Shapiro D, Kaufman KD, Amatruda JM (June 2010). "A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes". Diabetes, Obesity & Metabolism. 12 (6): 517–31. doi:10.1111/j.1463-1326.2009.01188.x. PMID 20518807.
  6. ↑ Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanshi S, Jones ME, Johnson-Levonas AO, Heymsfield SB, Kaufman KD, Amatruda JM (August 2010). "A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study". International Journal of Obesity (2005). 34 (8): 1243–54. doi:10.1038/ijo.2010.38. PMID 20212496.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.